S. Mukherjee

发表

Mutational Landscape of Therapy‐Related Myeloid Neoplasms: MDS‐304

J. Maciejewski, Y. Nagata, H. Carraway, 2018, Clinical Lymphoma, Myeloma & Leukemia.

The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation.

S. Mukherjee, C. Guidry, 2007, Investigative ophthalmology & visual science.

Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase

M. Kalaycio, S. Mukherjee, 2016, Current Hematologic Malignancy Reports.

Is the cure the poison? The evolving story of therapy-related myeloid malignancies

M. Sekeres, S. Mukherjee, 2015, Leukemia & lymphoma.

What’s All the Fuss About? Facts and Figures About Bone Marrow Failure and Conditions

M. Sekeres, S. Mukherjee, 2012, Current Hematologic Malignancy Reports.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities.

M. Sekeres, S. Mukherjee, E. Copelan, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

G. Guyatt, G. Abel, A. Agarwal, 2020, Blood advances.

Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series

M. Sekeres, S. Mukherjee, A. Gerds, 2018, Clinical lymphoma, myeloma & leukemia.

Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2020, Leukemia & lymphoma.

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes

J. Maciejewski, A. Advani, M. Sekeres, 2016, Leukemia & lymphoma.

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

J. Radich, F. Ravandi, M. Othus, 2018, Blood.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes

J. Maciejewski, H. Carraway, A. Advani, 2017, Leukemia.

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

M. Broder, E. Chang, C. Cogle, 2017, The oncologist.

Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy

C. Cogle, S. Mukherjee, T. Bentley, 2016, Expert review of pharmacoeconomics & outcomes research.

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

J. Maciejewski, H. Carraway, A. Advani, 2016, Leukemia.

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

S. Shetty, A. Advani, M. Sekeres, 2015, Clinical lymphoma, myeloma & leukemia.

More is better: combination therapies for myelodysplastic syndromes.

M. Sekeres, S. Mukherjee, M. Ornstein, 2015, Best practice & research. Clinical haematology.

Resuscitating a Dying Marrow: the Role of Hematopoietic Growth Factors

S. Mukherjee, Aakriti Pandita, 2014, Current Hematologic Malignancy Reports.

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study

M. Tormo, C. McMahon, T. Cluzeau, 2020, Leukemia.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

J. Maciejewski, H. Carraway, A. Advani, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.

J. Maciejewski, H. Carraway, M. Sekeres, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A case of hypereosinophilic syndrome with STAT5b N642H mutation

Subha Ghosh, S. Mukherjee, S. Krishnan, 2021, Oxford medical case reports.

Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome

J. Maciejewski, Y. Nagata, Y. Saunthararajah, 2019, Leukemia.

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms

J. Maciejewski, Y. Nagata, M. Sekeres, 2018, Leukemia.

Preview : Published ahead of advance online publication Distinct clinical and biological implications of various DNMT 3 A mutations in myeloid neoplasms

J. Maciejewski, Y. Nagata, M. Sekeres, 2017 .

Novel Therapies in Acute Myeloid Leukemia.

M. Sekeres, S. Mukherjee, 2019, Seminars in oncology nursing.

Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy

J. Maciejewski, Y. Saunthararajah, A. Advani, 2015, Leukemia & lymphoma.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

J. Rossi, E. Jaffe, N. Munshi, 2018, Blood.

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

É. Oksenhendler, A. Bagg, M. Lim, 2020, American journal of hematology.

Special Report International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

J. Rossi, E. Jaffe, N. Munshi, 2019 .

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Initiation of venovenous extracorporeal membrane oxygenation in a patient receiving induction chemotherapy for acute myelogenous leukemia

S. Mukherjee, M. R. Qureshi, S. Avasarala, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Blood consult: treating del(5q) myelodysplastic syndromes.

M. Sekeres, S. Mukherjee, R. Tiu, 2012, Blood.

Cigarette Smoking Significantly Increases the Risk of Invasive Fungal Disease (IFD) in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy

J. Maciejewski, Y. Saunthararajah, A. Advani, 2011 .

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

J. Radich, F. Ravandi, M. Othus, 2016 .

Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best

J. Maciejewski, H. Carraway, A. Advani, 2016 .

TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS)

J. Maciejewski, B. Jha, H. Carraway, 2016 .

A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia.

S. Mukherjee, A. Gerds, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

T. Haferlach, G. Garcia-Manero, J. Maciejewski, 2018, Blood.

Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

J. Maciejewski, H. Carraway, A. Advani, 2022, Bone Marrow Transplantation.

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models

E. Estey, M. Sorror, B. Sandmaier, 2016 .

Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia

F. Solé, J. Maciejewski, Y. Nagata, 2020, Leukemia & lymphoma.

Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia

M. Sekeres, E. Hsi, H. Rogers, 2015, Leukemia & lymphoma.

The Revised International Prognostic Scoring System Molecular (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS)

J. Maciejewski, H. Carraway, A. Advani, 2015 .

Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review

S. Mukherjee, M. Rehman, Abdul Rafae, 2021, European journal of haematology.

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy

D. Fajgenbaum, S. Mukherjee, J. Paige, 2021, Blood advances.

Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)

J. Ciezki, C. Reddy, E. Klein, 2011 .

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis

D. Fajgenbaum, S. Mukherjee, K. Kanhai, 2022, Leukemia.

Long-term survival of patients with therapy-related myeloid neoplasms after allogeneic hematopoietic cell transplantation—more than just a myth

S. Mukherjee, A. Gerds, 2016, Bone Marrow Transplantation.

Phenotype-associated changes in retinal pigment epithelial cell expression of insulin-like growth factor binding proteins.

S. Mukherjee, C. Guidry, J. L. King, 2009, Investigative ophthalmology & visual science.

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

E. Estey, F. Appelbaum, M. Othus, 2016, Leukemia.

Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality

E. Estey, M. Sorror, B. Storer, 2015 .

R. Larson, M. Liedtke, R. Levine, 2019, Blood advances.

Myeloid neoplasm with eosinophilia and ETV6-JAK2 fusion

H. Rogers, S. Mukherjee, J. Cook, 2020, Leukemia & lymphoma.

Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.

S. Mukherjee, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anemia Management With Darbepoetin-Alfa in Outpatient Hemodialysis Patients Switched From Epoetin-Alfa: A Community Hospital Experience

F. Dumler, S. Mukherjee, V. Agrawal, 2010, American journal of therapeutics.

Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data

G. Cooper, A. Avery, N. Schiltz, 2022, Cancer.

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review

G. Guyatt, S. Alibhai, M. Sekeres, 2022, PloS one.

A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.

T. Gildea, S. Mukherjee, N. Chaisson, 2018, Chest.

A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients

Chad M. Glen, D. Fajgenbaum, S. Mukherjee, 2020 .

S. Mukherjee, A. Zeidan, Abdallah Abou Zahr, 2017, Blood reviews.

Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes

J. Maciejewski, H. Carraway, A. Advani, 2015 .

Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight

J. Maciejewski, A. Advani, M. Sekeres, 2013, American journal of hematology.

Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review

G. Guyatt, G. Abel, C. Hourigan, 2021, PloS one.

Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.

S. Miyano, Y. Shiraishi, K. Chiba, 2015, Cancer cell.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

J. Maciejewski, H. Carraway, A. Advani, 2018, Blood Cancer Journal.

Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature.

I. Jaiyesimi, S. Mukherjee, A. D’Souza, 2010, Clinical lymphoma, myeloma & leukemia.

Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.

J. Ciezki, C. Reddy, E. Klein, 2014, Journal of the National Cancer Institute.

Incidence, Clinical Features, and Outcomes of Langerhans Cell Histiocytosis in the United States

T. Radivoyevitch, S. Mukherjee, I. Buhtoiarov, 2022, Journal of pediatric hematology/oncology.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J. Armitage, H. Rugo, G. Lyman, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

E. Estey, M. Sorror, B. Storer, 2017, JAMA oncology.

Influence of Killer Immunoglobulin-like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia.

J. Maciejewski, H. Carraway, A. Advani, 2021, Transplantation and cellular therapy.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine

J. Maciejewski, H. Carraway, A. Advani, 2018, Leukemia.

Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.

M. Sekeres, M. Kalaycio, P. Elson, 2015, Journal of oncology practice.

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

J. Maciejewski, Y. Nagata, H. Carraway, 2018, Clinical Cancer Research.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

J. Maciejewski, J. Pink, H. Carraway, 2019, Clinical Cancer Research.

Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation

D. Brenner, R. Sachs, J. Maciejewski, 2016, Leukemia.

Predictive factors for latency period and a prognostic model for survival in patients with therapy‐related acute myeloid leukemia

J. Maciejewski, Y. Saunthararajah, A. Advani, 2014, American journal of hematology.

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

T. Haferlach, G. Garcia-Manero, J. Maciejewski, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

T. Haferlach, J. Maciejewski, Y. Nagata, 2019, Blood.

Genomics of therapy-related myeloid neoplasms

J. Maciejewski, B. Jha, Y. Nagata, 2020, Haematologica.

The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies

M. Sekeres, M. Kalaycio, T. Radivoyevitch, 2017, Leukemia.

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes

T. Haferlach, J. Maciejewski, B. Jha, 2021, Blood Advances.

Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy

J. Maciejewski, H. Carraway, A. Advani, 2015 .

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

E. Jabbour, Dajun Yang, Y. Zhai, 2022, Blood.

Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.

R. Cerfolio, C. Katholi, S. Mukherjee, 2003, The Journal of thoracic and cardiovascular surgery.

Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response

M. Liedtke, H. Carraway, A. Advani, 2018, Leukemia & lymphoma.

Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes

S. Miyano, T. LaFramboise, Y. Shiraishi, 2019, Nature Communications.

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.

Ashutosh Kumar Singh, K. Stange, H. Carraway, 2023, The oncologist.

A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia

T. Haferlach, J. Maciejewski, H. Carraway, 2022, Blood.

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies

M. Broder, E. Chang, Gordon H. Sun, 2014 .

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

J. Maciejewski, Y. Saunthararajah, H. Carraway, 2015 .

Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review

S. Mukherjee, M. Rehman, Abdul Rafae, 2022, European journal of haematology.

Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.

M. Sekeres, M. Kalaycio, P. Elson, 2015, Journal of oncology practice.

Preview : Published ahead of advance online publication The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies

M. Sekeres, M. Kalaycio, T. Radivoyevitch, 2016 .

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

B. Hobbs, H. Carraway, A. Advani, 2019, Blood.

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

H. Carraway, A. Advani, M. Sekeres, 2020 .

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

J. Maciejewski, H. Carraway, A. Advani, 2017 .

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

E. Estey, M. Sorror, B. Sandmaier, 2018, Blood.

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

H. Kantarjian, E. Jabbour, Dajun Yang, 2023, Blood.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

J. Maciejewski, H. Carraway, A. Advani, 2018, Blood Cancer Journal.